← Back to Search

Chemotherapy

Angiomammography for Breast Cancer Response Prediction

N/A
Recruiting
Research Sponsored by CHU de Quebec-Universite Laval
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
No evidence of distant metastasis
Histologically proven breast cancer by large gauge needle
Must not have
Significant kidney failure
Frank hyperthyroidism
Timeline
Screening 3 weeks
Treatment Varies
Follow Up cycle 2 (each cycle being 21 days), i.e., after the chemotherapy on day 1 of cycle 2 and before cycle 3.
Awards & highlights

Summary

This trial is looking at whether a less expensive and more readily available diagnostic modality, namely CESM, is as effective as MRI in predicting the response of a malignant breast tumor to neoadjuvant chemotherapy and the chances of achieving a pCR.

Who is the study for?
This trial is for women over 18 with breast cancer that hasn't spread far (no distant metastasis), measurable by examination. They must be undergoing neoadjuvant chemotherapy, possibly with additional targeted therapy. Exclusions include pregnancy, allergies to contrast dye, MRI contraindications, overt hyperthyroidism, and significant kidney failure.Check my eligibility
What is being tested?
The study compares two imaging techniques—CESM and MRI—to see which better predicts the absence of invasive cancer cells in the breast and lymph nodes after early rounds of chemotherapy. This could help switch treatments sooner for those not responding well.See study design
What are the potential side effects?
Potential side effects may relate to the use of contrast dyes during imaging tests such as allergic reactions or kidney issues. The MRI might not be suitable for people with certain implants or claustrophobia.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My cancer has not spread to distant parts of my body.
Select...
My breast cancer was confirmed with a biopsy.
Select...
My breast tumor can be felt and measured by a doctor.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have severe kidney problems.
Select...
I have an overactive thyroid.
Select...
I refuse to undergo a biopsy or surgery.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~cycle 2 (each cycle being 21 days), i.e., after the chemotherapy on day 1 of cycle 2 and before cycle 3.
This trial's timeline: 3 weeks for screening, Varies for treatment, and cycle 2 (each cycle being 21 days), i.e., after the chemotherapy on day 1 of cycle 2 and before cycle 3. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of patients with a pCR accoreding to angiomammography, based on a 50% reduction in lesion size at angiomammography

Trial Design

1Treatment groups
Experimental Treatment
Group I: Neoadjuvant chemotherapyExperimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

CHU de Quebec-Universite LavalLead Sponsor
168 Previous Clinical Trials
107,401 Total Patients Enrolled
4 Trials studying Breast Cancer
1,097 Patients Enrolled for Breast Cancer

Media Library

Neoadjuvant Chemotherapy (Chemotherapy) Clinical Trial Eligibility Overview. Trial Name: NCT05402930 — N/A
Breast Cancer Research Study Groups: Neoadjuvant chemotherapy
Breast Cancer Clinical Trial 2023: Neoadjuvant Chemotherapy Highlights & Side Effects. Trial Name: NCT05402930 — N/A
Neoadjuvant Chemotherapy (Chemotherapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05402930 — N/A
~6 spots leftby Dec 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top